Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
266 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016', provides an overview of the Takeda Pharmaceutical Company Limited's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Takeda Pharmaceutical Company Limited - The report provides overview of Takeda Pharmaceutical Company Limited including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Takeda Pharmaceutical Company Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Takeda Pharmaceutical Company Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Takeda Pharmaceutical Company Limited's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Takeda Pharmaceutical Company Limited - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Takeda Pharmaceutical Company Limited's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Takeda Pharmaceutical Company Limited Snapshot 7 Takeda Pharmaceutical Company Limited Overview 7 Key Information 7 Key Facts 7 Takeda Pharmaceutical Company Limited - Research and Development Overview 8 Key Therapeutic Areas 8 Takeda Pharmaceutical Company Limited - Pipeline Review 15 Pipeline Products by Stage of Development 15 Pipeline Products - Monotherapy 16 Pipeline Products - Combination Treatment Modalities 17 Pipeline Products - Partnered Products 18 Pipeline Products - Out-Licensed Products 20 Takeda Pharmaceutical Company Limited - Pipeline Products Glance 22 Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products 22 Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products 25 Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products 28 Takeda Pharmaceutical Company Limited - Drug Profiles 33 (alogliptin benzoate + metformin hydrochloride) 33 (alogliptin benzoate + pioglitazone hydrochloride) 35 brentuximab vedotin 38 ceftaroline fosamil 45 ixazomib citrate 48 ramelteon 53 vedolizumab 55 roflumilast 57 (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) 62 azilsartan medoxomil 63 febuxostat XR 65 immune globulin (human) 66 pioglitazone hydrochloride 68 rasagiline mesylate 70 relugolix 71 TAK-003 72 vortioxetine hydrobromide 75 AM-4 78 DSM-265 79 namilumab 81 TAK-063 83 TAK-214 85 TAK-272 87 TAK-850 88 J-591 90 TAK-020 91 TAK-021 92 TAK-058 93 TAK-071 94 TAK-079 95 TAK-653 96 TAK-792 97 TAK-828 98 TAK-831 99 TAK-915 100 TAK-935 101 trelagliptin succinate 102 (plague + small pox) vaccine 104 BTZO-2 105 chikungunya vaccine 106 ELQ-300 107 influenza [strain A/H5N1] vaccine 108 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine 109 mapatumumab 110 Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer 112 Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology 113 Monoclonal Antibody Conjugates for Oncology 114 respiratory syncytial virus (virus like particle) vaccine 115 Rotavirus (virus like particle) vaccine 116 Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 117 Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease 118 Small Molecule to Activate Glucokinase for Type 2 Diabetes 119 Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain 120 Small Molecule to Agonize GPR52 for Psychiatry Disorders 121 Small Molecule to Antagonize Androgen Receptor for Prostate Cancer 122 Small Molecule to Antagonize CRF1 for CNS Disorders 123 Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia 124 Small Molecule to Antagonize MCHR1 for Obesity 125 Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension 126 Small Molecule to Antagonize PDGFR and VEGFR-2 for Oncology 127 Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 128 Small Molecule to Inhibit FAAH for Pain 129 Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease 130 Small Molecule to Inhibit HER2/EGFR for Oncology 131 Small Molecule to Inhibit NET for Stress Urinary Incontinence 132 Small Molecule to Inhibit PKC-Theta 133 Small Molecules for Parkinson's Disease 134 Small Molecules for Visceral Leishmaniasis 135 Small Molecules to Agonize GPR119 for Type II Diabetes 136 Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity 137 Small Molecules to Inhibit B-Raf for Oncology 138 Small Molecules to Inhibit CENP-E for Colon Cancer 139 Small Molecules to Inhibit DPP-IV for Type 2 Diabetes 140 Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma 141 Small Molecules to Inhibit MAP2 for Obesity 142 Small Molecules to Inhibit MGAT2 for Metabolic Disorders 143 Small Molecules to Inhibit MMP-13 for Osteoarthritis 144 Small Molecules to Inhibit PARP-1 for Colon Cancer 145 Small Molecules to Inhibit TYK2 146 Stem Cell Therapy for Muscular Dystrophy 147 T-1840383 148 T-3256336 149 TAK-041 150 TAK-480 151 TAK-632 152 Y-443 153 Small Molecule for Undisclosed Indication 154 Small Molecule to Inhibit Arginine Methyltrasferase for Oncology 155 Small Molecule to Inhibit HDAC6 156 Small molecules for Leishmaniasis and Trypanosomiasis 157 Small Molecules for Malaria 158 Small Molecules for Tuberculosis 159 Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 160 Small Molecules to Inhibit FAK for Oncology 161 Small Molecules to Inhibit HER2 and EGFR for Oncology 162 Small Molecules to Inhibit IAP for Oncology 163 Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology 164 Y-142 165 Takeda Pharmaceutical Company Limited - Pipeline Analysis 166 Takeda Pharmaceutical Company Limited - Pipeline Products by Target 166 Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration 176 Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type 177 Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action 178 Takeda Pharmaceutical Company Limited - Recent Pipeline Updates 188 Takeda Pharmaceutical Company Limited - Dormant Projects 232 Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products 235 Discontinued Pipeline Product Profiles 237 Takeda Pharmaceutical Company Limited - Company Statement 246 Takeda Pharmaceutical Company Limited - Locations And Subsidiaries 247 Head Office 247 Other Locations & Subsidiaries 247 Appendix 257 Methodology 257 Coverage 257 Secondary Research 257 Primary Research 257 Expert Panel Validation 257 Contact Us 257 Disclaimer 258
List of Tables
Takeda Pharmaceutical Company Limited, Key Information 15 Takeda Pharmaceutical Company Limited, Key Facts 15 Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2016 17 Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016 23 Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016 24 Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016 25 Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016 26 Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2016 27 Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016 28 Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 29 Takeda Pharmaceutical Company Limited - Pre-Registration, 2016 30 Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2016 31 Takeda Pharmaceutical Company Limited - Phase III, 2016 32 Takeda Pharmaceutical Company Limited - Phase II, 2016 33 Takeda Pharmaceutical Company Limited - Phase I, 2016 34 Takeda Pharmaceutical Company Limited - Phase 0, 2016 35 Takeda Pharmaceutical Company Limited - IND/CTA Filed, 2016 36 Takeda Pharmaceutical Company Limited - Preclinical, 2016 37 Takeda Pharmaceutical Company Limited - Discovery, 2016 40 Takeda Pharmaceutical Company Limited - Pipeline by Target, 2016 174 Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016 184 Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016 185 Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2016 186 Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2016 196 Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2016 240 Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2016 243 Takeda Pharmaceutical Company Limited, Other Locations 255 Takeda Pharmaceutical Company Limited, Subsidiaries 255
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
